Santen Pharmaceutical Co., Ltd.

4536

JP3336000009

Pharmaceuticals

Delayed Japan Exchange Other stock markets 03:30:00 18/07/2024 BST			5-day change	1st Jan Change
1,852 ^JPY	+2.43%		+3.32%	+31.78%

07-01	Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 9, 2024.	CI
05-10	Santen Pharmaceutical Intends to Buy Back and Cancel up to 38 Billion Yen Worth of Shares	MT

Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 8, 2022.

January 05, 2023 at 07:00 am

From November 8, 2022 to December 31, 2022, the company has repurchased 4,427,600 shares, representing 1.14% for Ã‘4,900.29 million. With this, the company has completed the repurchase of 4,427,600 shares, representing 1.14% for Ã‘4,900.29 million under the buyback announced on November 8, 2022.

Latest news about Santen Pharmaceutical Co., Ltd.

Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 9, 2024.	07-01	CI
Santen Pharmaceutical Intends to Buy Back and Cancel up to 38 Billion Yen Worth of Shares	05-10	MT
Santen Pharmaceutical Co., Ltd. announces an Equity Buyback for 21,110,000 shares, representing 5.81% for ¥38,000 million.	05-09	CI
Santen Pharmaceutical Co., Ltd. Provides Year End Dividend Guidance for the Full Year Ending March 31, 2025	05-09	CI
Santen Pharmaceutical Co., Ltd. Announces Year End Dividend for the Year Ended March 31, 2024, Payable on June 26, 2024; Provides Dividend Guidance for the End of Second Quarter of 2025	05-09	CI
Santen Pharmaceutical Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2025	05-09	CI
Santen Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	05-08	CI
Santen Pharmaceutical to Cancel 12 Million Treasury Shares	03-26	MT
Santen Announces Re-Designation Akira Kurokawa as Director of the Board and Chairman from Representative Director of the Board, Chairman, Effective from April 1, 2024	03-25	CI
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.	03-25	CI
Santen Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 11, 2023, has closed with 12,571,400 shares, representing 3.38% for ¥16,178.35 million.	03-21	CI
Santen Pharmaceutical's Returns to the Black in Fiscal Nine Months	02-09	MT
Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024	02-08	CI
Jefferies Adjusts Santen Pharmaceutical’s Price Target to 1,700 Yen From 1,650 Yen, Keeps at Buy	01-29	MT
Santen Pharmaceutical Further Repurchases Shares for Over 1 Billion Yen	01-08	MT
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.	01-05	CI
Santen Pharmaceutical Buys Back Nearly 2 Billion Yen of Shares	12-04	MT
Santen Pharmaceutical’s Fiscal H1 EPS Increases to 69.68 Yen as Net Sales Rise 13.1% to 145.81 Billion Yen; Declares Interim Dividend of 16 Yen Per Share, Maintains Forecast	11-08	MT
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024	11-07	CI
Santen Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on November 30, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	11-07	CI
Santen Pharmaceutical Buys Back 523,400 shares for 772.6 Million Yen in September	03/10/23	MT
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023.	02/10/23	CI
Jefferies Adjusts Santen Pharmaceutical’s Price Target to 1,650 Yen From 1,400 Yen, Keeps at Buy	21/09/23	MT
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024	20/09/23	CI
Santen Pharmaceutical Co., Ltd. Provides Dividend Forecasts for Second Quarter of 2024 and the Fiscal Year Ending March 31, 2024	03/08/23	CI

Chart Santen Pharmaceutical Co., Ltd.

Duration

Period

More charts

Company Profile

SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The Company engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The Company operates in Japan, Europe, Asia, North America markets.

Sector

Pharmaceuticals

Calendar

05/08/2024 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Santen Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,808 JPY

Average target price

1,868 JPY

Spread / Average Target

+3.35%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANTEN PHARMACEUTICAL CO., LTD.	+31.78%	3.98B
ELI LILLY AND COMPANY	+55.35%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.10%	363B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+13.10%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.54%	179B
PFIZER, INC.	+4.31%	167B

Other Pharmaceuticals

Santen Pharmaceutical Co., Ltd.

Equities

4536

JP3336000009

Pharmaceuticals

Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 8, 2022.

EPS Revisions